Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Alacrita and Debiopharm Group™ Collaborate

Published: Tuesday, June 25, 2013
Last Updated: Tuesday, June 25, 2013
Bookmark and Share
Collaboration to identify early stage drug candidates from the Massachusetts life science cluster.

Alacrita and Debiopharm Group™ (Debiopharm) have established an alliance to identify oncological, autoimmune, infectious diseases as well as metabolic in-licensing opportunities stemming from the Massachusetts life science cluster.

Alacrita will strengthen Debiopharm’s in-house scouting team in their search for small molecules, antibody or peptide-based product candidates.

The companies are seeking preclinical assets against novel targets which represent first-in-class opportunities.

Debiopharm focuses on the development of prescription drugs that target unmet medical needs. The company recently in-licensed assets from two Massachusetts companies, including Mercury Therapeutics Inc. (Woburn, MA) and Curis Inc. (Lexington, MA).

In recognition of the depth and breadth of life science innovation in Massachusetts, Debiopharm sees the value of a local presence in the region and has selected Alacrita as its representative.

Alacrita is also in charge of identifying opportunities for Debiopharm elsewhere on the East Coast.

David Deperthes, Vice President, Business Development & Licensing at Debiopharm said: “Massachusetts hosts global leaders in pharmaceutical innovation. As such, the area represents a strategic priority for us as we source opportunities from around the world to expand our pipeline of novel medicines. We are delighted to be working with Alacrita, a leading pharma consultancy on both sides of the Atlantic.”

Rob Johnson, Partner at Alacrita Consulting, said: “Debiopharm’s resources and expertise in global pharmaceutical development make it an ideal partner for Massachusetts organizations looking to move their preclinical programs into clinical trials. Debiopharm has a track record of shepherding early stage pharmaceutical programs into late stage clinical trials and has demonstrated extraordinary success in delivering new medical breakthroughs to patients, a testament to its impressive preclinical, clinical, manufacturing, drug delivery, formulation and regulatory expertise. Alacrita is proud to have been selected by Debiopharm to source new in-licensing opportunities for the group and enable the next generation of medical products.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Signaling Molecule Regulates Release of the Hunger Hormone Ghrelin
Researchers at UT Southwestern have identified that the blocking release of the hormone ghrelin may mediate low blood sugar effect in children taking beta blockers.
Telomere Replenishment in Real Time
Researchers have visualised the process of telomere attachment to chromosomes through single-molecule imaging.
New Inflammatory Disease Discovered
NIH researchers have discovered a rare and potentially deadly disease - otulipenia - the mostly affects children.
World's Most In-Depth Study to Detect Alzheimer's Disease
A multisite team will see the most thorough and vigorous testing for Alzheimer's ever performed on volunteers.
Zika Proteins Responsible for Microcephaly Identified
Researchers have undertaken the first study to examine Zika infection in human neural stem cells from second-trimester fetuses.
Pinpointing Key Influenza-Fighting Immune Trigger
Immunologists have identified the protein trigger that recognises influenza virus infection in cells and triggers their death.
Uncovering Constructor Proteins
Scientists have discovered a new bacterial cell wall builder that could be a target for antibiotic development.
Studying Protein, Synapse Interactions
New research identifies, for the first time, the role of certain proteins in synapse opperation and function.
Biomarker Breakthrough Could Improve Parkinson’s Treatment
A new method of tracking Parkinson's progression could aid evaluation of new and experimental treatments to slow or stop the disease.
PARP Proteins Explore Therapeutic Targets in Cancer
Researchers at UTSW have identified a previously unknown role of a certain class of proteins that opens the door to explore therapeutic targets in cancer and other disease.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!